Table 4.
Comparison between patients that received complete COVID-19 vaccination schedule and unvaccinated patients
| Characteristics (N = 356) | Vaccinated patients N = 327 (91.8%) |
Unvaccinated patients N = 29 (8.2%) |
p value |
|---|---|---|---|
| Age [years], median (IQR) | 76 (63–84) | 78 (61–86) | 0.946 |
| Male sex, n (%) | 183 (56%) | 14 (48.3%) | 0.425 |
| Risk factor, n (%): | |||
| Age ≥ 65 years | 214 (65.4%) | 20 (69%) | 0.702 |
| BMI ≥ 30 | 26 (8%) | 2 (6.9%) | 0.840 |
| Cardiovascular disease | 127 (38.8%) | 12 (41.4%) | 0.788 |
| COPD or other respiratory disease | 68 (20.8%) | 8 (27.6%) | 0.392 |
| Neurological disease | 32 (9.8%) | 3 (10.3%) | 0.923 |
| Diabetes mellitus | 58 (17.7%) | 5 (17.2%) | 0.947 |
| Chronic kidney failure | 19 (5.8%) | 2 (6.9%) | 0.812 |
| Cancer | 28 (8.6%) | 2 (6.9%) | 0.757 |
| Immunodeficiency | 46 (14.1%) | 3 (10.3%) | 0.577 |
| Calendar period: | 0.803 | ||
| Jan–May | 150 (45.9%) | 14 (48.3%) | |
| Jun–Oct | 177 (54.1%) | 15 (51.7%) | |
| Antiviral treatment: | 0.487 | ||
| Nirmatrelvir/ritonavir | 121 (37%) | 14 (48.3%) | |
| Molnupiravir | 84 (25.7%) | 6 (20.7%) | |
| Remdesivir | 122 (37.3%) | 9 (31%) | |
| Setting, n (%): | 0.388 | ||
| Outpatient service | 249 (76.1%) | 20 (69%) | |
| Hospitalization for diseases other than COVID-19 | 78 (23.9%) | 9 (31%) | |
| Days from symptom onset to antiviral treatment, median (IQR) | 2 (1–4) | 2 (1–3) | 0.310 |
| Days from symptom onset to virological clearance, median (IQR) | 12 (9–17) | 16 (12–21) | 0.012 |
| Outcome, n (%): | N 288 | N 27 | 0.530 |
| Recovery | 277 (96.2%) | 27 (100%) | |
| Death | 11 (3.8%) | 0 | |
| Adverse events, n (%): | 0.907 | ||
| No | 317 (96.9%) | 28 (96.6%) | |
| Yes | 10 (3.1%) | 1 (3.4%) | |
| Virological clearance at day 7 from symptoms onset, n (%): | N = 231 | N = 16 | 0.012 |
| No | 131 (56.7%) | 9 (56.3%) | |
| Yes | 100 (43.3%) | 7 (43.8%) |
Quantitative data are presented as median, interquartile range; categorical data are presented as absolute numbers, percentages. Mann–Whitney and Chi-squared test for comparison among the three groups, as appropriate
Days from symptom onset to virological clearance was defined as days from onset of symptoms to the first antigenic- or PCR-negative nasopharyngeal swab; virological clearance at day 7 was defined as patients with antigenic- or PCR-negative nasopharyngeal swab at day 7 after treatment start
BMI body mass index, COPD chronic obstructive pulmonary disease